In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the Quarter & Year ended ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gennex Laboratories reported audited standalone revenue from operations of ₹9,457.79 Lacs for FY25, up ~41.6% YoY from ₹6,679.87 Lacs, while standalone net profit rose ~19% to ₹1,403.68 Lacs (vs ₹1,179.79 Lacs). Consolidated revenue surged ~59% to ₹13,790.30 Lacs and consolidated net profit grew ~37.6% to ₹1,812.49 Lacs. However, Q4 standalone net profit fell sharply to ₹150.20 Lacs from ₹392.86 Lacs, dragged by higher material, employee and finance costs. The statutory auditor (R Pugalia & Company) issued a qualified opinion on both standalone and consolidated results, citing pending confirmations/reconciliations of various asset and liability balances with unascertainable impact — flagged as a repetitive qualification. The Board also appointed Mr. Sandeep Kumar Daga as Non-Executive Non-Independent Director and noted the resignation of Dr. S CH Dharma Rao.
Strong full-year revenue and profit growth is encouraging, but the recurring qualified audit opinion, sharply weaker Q4 standalone profits, margin compression, and negative operating cash flows point to unresolved accounting reconciliations and rising costs that shareholders should monitor closely.